350 million people live with depression worldwide\(^1\)
26 million people live with schizophrenia worldwide\(^2\)
14 million people live with alcohol dependence in Europe\(^3\)

Our foundation for progress

More than 700 million people are affected by brain disease worldwide – this is equal to 13% of the global disease burden.

Brain disease is a global health problem: Through improved medical treatments and continuous focus on the unmet needs of patients, we want to address the issue and call for greater awareness of the massive economic and societal burden brain disease represents.

Progress in Mind is Lundbeck’s dedication to addressing the global burden of brain disease.

With a company history dating back to 1915, and with more than 50 years as experts in neuroscience research, Lundbeck is a fully-integrated pharmaceutical company specialized within the treatment of brain disease.

75% of Lundbeck shares are owned by the Lundbeck Foundation, which is dedicated to maintaining and expanding Lundbeck’s research activities. The knowledge we generate is communicated worldwide to health care professionals and leading medical experts through our unique educational initiatives, such as the activities run globally by the Lundbeck Institute.

With our unique position as a specialist in brain disease, we want to raise disease awareness and challenge the international agenda for broader acceptance of patients and increased opportunities for better treatment.

Want to know more? Go to: www.lundbeck.com/global/about-us/progress-in-mind
www.youtube.com/user/progressinmind

Why should people with brain disease live 10–20 years less than others?\(^1\)
Why do almost 50% of people with brain diseases not receive any treatment?\(^2\)
Why do more than 70% of people living with brain disease experience discrimination?\(^3\)

Improved treatment and a better life for people living with brain disease

All over the world, brain disease is a growing burden, not only for individuals but for families and societies as well. An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences.

Lundbeck is a specialized pharmaceutical company focusing on brain disease. For more than 50 years, we have been at the forefront of research within neuroscience and our development and distribution of pioneering treatments continues to make a difference to people living with brain disease. We are recognized for having helped hundreds of millions of people suffering from brain disease, such as depression, alcohol dependence, schizophrenia, epilepsy, and Alzheimer’s, Parkinson’s and Huntington’s disease. However, there is still a massive need for help.

Every day, we strive for improved treatment and a better life for people living with brain disease—we call this Progress in Mind.

Global progress for people living with brain disease requires a multifaceted approach. First and foremost, we continue to develop new and improved medical treatments and continue to focus on the patient, ensuring that he or she regains possibilities. But we also work to embrace our mission from two other essential dimensions: We encourage increased support for affected families and we engage in communities to create broader social acceptance of patients.

To raise awareness and prevent stigmatization, we use our voice as experts in brain disease and share our knowledge about the many unmet needs in the treatment of brain disease. We reach into both professional and patient communities to offer disease education and support programmes to healthcare professionals and patients and their families. Our global presence enables us to let successful, local initiatives travel the world and make a difference to patients everywhere.

To create successful treatments, being dedicated to the patient and his or her specific needs is crucial and provides any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.

Meeting unmet needs of patients

The best way to help patients is to always have their needs as our first priority. This core understanding drives our commitment to innovation within brain disease. It also strengthens our ability to bring research forward, and it means that we will continue our active engagement with patients. Our specialists develop new drugs based on a deep insight into the brain, the specific diseases, and the unmet needs of patients. In order to create successful treatments, being dedicated to the patient and his or her specific needs is crucial and provides any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.

Meeting unmet needs of patients

The best way to help patients is to always have their needs as our first priority. This core understanding drives our commitment to innovation within brain disease. It also strengthens our ability to bring research forward, and it means that we will continue our active engagement with patients. Our specialists develop new drugs based on a deep insight into the brain, the specific diseases, and the unmet needs of patients. In order to create successful treatments, being dedicated to the patient and his or her specific needs is crucial and provides any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.

Meeting unmet needs of patients

The best way to help patients is to always have their needs as our first priority. This core understanding drives our commitment to innovation within brain disease. It also strengthens our ability to bring research forward, and it means that we will continue our active engagement with patients. Our specialists develop new drugs based on a deep insight into the brain, the specific diseases, and the unmet needs of patients. In order to create successful treatments, being dedicated to the patient and his or her specific needs is crucial and provides any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.

Meeting unmet needs of patients

The best way to help patients is to always have their needs as our first priority. This core understanding drives our commitment to innovation within brain disease. It also strengthens our ability to bring research forward, and it means that we will continue our active engagement with patients. Our specialists develop new drugs based on a deep insight into the brain, the specific diseases, and the unmet needs of patients. In order to create successful treatments, being dedicated to the patient and his or her specific needs is crucial and provides any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.

Meeting unmet needs of patients

The best way to help patients is to always have their needs as our first priority. This core understanding drives our commitment to innovation within brain disease. It also strengthens our ability to bring research forward, and it means that we will continue our active engagement with patients. Our specialists develop new drugs based on a deep insight into the brain, the specific diseases, and the unmet needs of patients. In order to create successful treatments, being dedicated to the patient and his or her specific needs is crucial and provides any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.